IQWiG assesses benefit of negative pressure wound therapy (NPWT) in Germany

20

Dec 2017

The Federal Joint Committee (G-BA) routinely performs assessments of treatment methods that are included as a benefit in within the Statutory Health Insurance (SHI) in Germany. For this, it can request Health Technology Assessment (HTA) reports by the German Institute for Quality and Efficiency in Health Care (IQWiG).

Negative pressure wound therapy (NPWT) is a therapeutic method that uses a vacuum dressing to promote healing of chronic or acute wounds, for instance heavy burns and diabetic ulcers. For this, sub-atmospheric pressure is applied to the wound environment with the help of a vacuum pump which is connected to the sealed wound dressing. The use of NWPT in wound management has increased significantly in the past years.

In April 2017, the G-BA decided to re-assess the use of NWPT. For this purpose, it charged the IQWiG with the task to prepare an HTA report about the benefit of NWPT compared to conventional wound treatment methods. The comparison of different NWPT methods among each other are not in the scope of the method. A report with similar research questions has been performed in 2016 and updated in 2017. The new report will assess the new evidence that was published since then. Only randomised controlled trials (RCTs) will be included as relevant scientific literature in the benefit assessment.

NWPT is currently reimbursed without limitations in the inpatient sector in Germany. The new evaluation report by IQWiG will support the G-BA’s decision about further inclusion of the method within the statutory health insurance in Germany.

The final project plan by IQWiG is available in German here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

09

Mar 2022

On February 16, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has published the decisions which recommended the transfer to standard care for three completed projects. The projects relate to the prevention of antibiotic resistance, improvement of healthcare in socially disadvantaged areas, and misuse of control colonoscopies in Germany.

Read more

03

Mar 2022

In February 2022, two more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, thirty health apps are now available at the DiGA Directory.

Read more

07

Feb 2022

On January 20, 2022, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for the use of a stent retriever (pRELAX by femtos) to treat vasospasm of cerebral arteries after subarachnoid hemorrhage.

Read more

28

Jan 2022

On December 26, 2021, the new health app was introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 28 health apps are now available at the DiGA Directory.

Read more